A phase ii study of carboplatin in nasopharyngeal carcinoma

Kwan H. Chi*, Yuan C. Chang, Wing K. Chan, Jacqueline M. Liu, Chi K. Law, Su S. Lo, Chih H. Shu, Shan H. Yen, Jacqueline Whang-Peng, Kuang Y. Chen

*此作品的通信作者

研究成果: Article同行評審

12 引文 斯高帕斯(Scopus)

摘要

This is a phase II study to evaluate the efficacy and toxicity of short-course carboplatin in advanced-stage nasopharyngeal carcinoma (NPC). Thirty-three previously untreated stage III-IV NPC patients were studied. Carboplatin was given as a rapid intravenous injection every 3 weeks. The dose of carboplatin was calculated according to the individual patient’s creatinine clearance and desired platelet nadir of 75,000/μl according to the Egorin formula. Response and toxicity were evaluated. Thirty-two patients were evaluated for response. The median age was 54 years, range 30-70 years. Twenty-four patients had local regional disease and 8 patients had metastatic disease. The median dose of carboplatin given was 415 mg/m2 (range 91-791 mg/m2). Fourteen (44%) patients had a partial response with a 95% confidence interval of 26-62%. Fifteen (47%) patients had stable disease and 3 (9%) progressive disease. The overall median survival rate was not reached at 43 months. Overall toxicity was tolerable. Grade III-IV myelosuppression occurred in 4 (12%) patients. There were no other major toxicity- or treatment-related deaths. We conclude that carboplatin has a significant anticancer effect in advanced NPC. Thus carboplatin combination chemotherapy for the treatment of NPC is worthy of future clinical investigations.

原文English
頁(從 - 到)203-207
頁數5
期刊Oncology (Switzerland)
54
發行號3
DOIs
出版狀態Published - 1 1月 1997

指紋

深入研究「A phase ii study of carboplatin in nasopharyngeal carcinoma」主題。共同形成了獨特的指紋。

引用此